We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?
Read MoreHide Full Article
Key Takeaways
Hinge Health stock is up nearly 90% YTD as Q2 revenues rose 53% and operating margin reached 29%.
HNGE raised 2026 revenue guidance to $856-$860M as member yield and AI-driven efficiencies improved.
Migraine Care and the planned Cylinder deal expand Hinge Health beyond MSK into migraine and GI care.
Hinge Health (HNGE - Free Report) stock has surged nearly 90% year to date, significantly outperforming the industry’s 1.7% gain and the S&P 500’s 12.6% rise. The sharp rally reflects growing investor confidence in the company’s strong growth trajectory, improving profitability and expanding digital healthcare platform.
Hinge Health’s second-quarter performance reinforced this momentum, with revenues jumping 53% year over year to $213 million. The company also raised its 2026 revenue guidance to $856-$860 million. Meanwhile, the launch of Migraine Care and planned expansion into gastrointestinal care are broadening its addressable market and could provide new growth avenues.
What Is Fueling HNGE’s Growth?
Durable Member Yield Is Driving Revenue Momentum: Hinge Health’s improving member yield has emerged as a key growth driver in 2026. In the second quarter, stronger yields helped push calculated billings to $862 million, up 52% year over year, while revenues jumped 53% to $213 million.
Management raised its full-year yield expectation to approximately 4.45%, citing targeted enrollment campaigns, member referrals and renewals. Faster member adoption among new clients and stronger engagement among legacy clients are also supporting the trend. These initiatives provide a durable foundation for continued revenue growth.
AI and Automation Are Expanding Operating Leverage: Hinge Health is using AI and automation to scale care delivery while controlling costs. Gross margin expanded more than 400 basis points year over year to 87% in the second quarter. Operating margin also increased 1,000 basis points to 29%.
The company is serving more members without proportional increases in care delivery costs, supported by greater care team efficiency and AI-driven workflows. Management expects 2026 operating income of $236-$244 million, up from its previous guidance of $217-$227 million.
Migraine Care Broadens HNGE’s Growth Opportunity: Hinge Health’s expansion beyond musculoskeletal care is creating another growth avenue. The Migraine Care Program had more than 450 clients covering more than 5 million lives by the second quarter, following its launch earlier in 2026. The offering combines AI-powered tracking, exercise therapy, care-team support and the Enso neuromodulation device.
Management expects only a modest revenue contribution in 2026, with a more meaningful impact beginning in 2027. The rapid client adoption highlights the ability of Hinge Health to leverage its existing platform and distribution network across new conditions.
GI Expansion Adds a New Growth Engine: Hinge Health is also expanding into gastrointestinal care through its planned $105 million acquisition of Cylinder Health. The deal adds nearly 100 clients covering 2 million lives and established relationships with major health plans and PBMs.
Hinge Health expects Cylinder to contribute $7-$8 million of revenues during the remaining months of 2026, with a much larger opportunity from 2027 onward. GI is a natural extension of the company’s multi-product strategy, as it can leverage the same technology, distribution channels and commercial relationships.
Image Source: Zacks Investment Research
HNGE’s Estimates
The Zacks Consensus Estimate for HNGE’s 2026 and 2027 earnings per share (EPS) implies a year-over-year decline of 4.6% and growth of 31.4%, respectively, to $2.50 and $3.29. In the past 60 days, the consensus mark for the company's 2026 EPS has improved by a cent.
Revenues for 2026 are projected to grow 44.6% to $850.3 million and another 25.4% to $1.07 billion in 2027.
Image Source: Zacks Investment Research
Risks and Challenges
HNGE’s rapid expansion also brings execution risks. The company is entering multiple new care categories while continuing to scale its core MSK business. The success of Migraine Care and the planned integration of Cylinder Health will depend on effective product development, client adoption and execution.
Member yield is also becoming increasingly important to the growth outlook. Any moderation in enrolment, engagement or renewals could weigh on billings and revenue. In addition, HNGE operates in a competitive digital healthcare market, where maintaining its strong win rates and client relationships will remain critical.
Conclusion
HNGE’s strong 2026 performance reflects a business that is scaling rapidly while becoming increasingly profitable. Robust revenue and billings growth, improving member yields, AI-driven efficiency and strong free cash flow point to a business model gaining operating leverage. At the same time, Migraine Care and the entry into GI are giving HNGE additional avenues to expand beyond its core MSK market. The company’s raised 2026 outlook and strong commercial pipeline further support the growth story.
However, execution across new products and the ability to sustain member engagement will remain key. With a Zacks Rank #3 (Hold), investors should weigh HNGE’s attractive growth prospects against the execution risks that come with its rapid expansion.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
View the Zacks #1 Rank List
Image: Bigstock
HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?
Key Takeaways
Hinge Health (HNGE - Free Report) stock has surged nearly 90% year to date, significantly outperforming the industry’s 1.7% gain and the S&P 500’s 12.6% rise. The sharp rally reflects growing investor confidence in the company’s strong growth trajectory, improving profitability and expanding digital healthcare platform.
Hinge Health’s second-quarter performance reinforced this momentum, with revenues jumping 53% year over year to $213 million. The company also raised its 2026 revenue guidance to $856-$860 million. Meanwhile, the launch of Migraine Care and planned expansion into gastrointestinal care are broadening its addressable market and could provide new growth avenues.
What Is Fueling HNGE’s Growth?
Durable Member Yield Is Driving Revenue Momentum: Hinge Health’s improving member yield has emerged as a key growth driver in 2026. In the second quarter, stronger yields helped push calculated billings to $862 million, up 52% year over year, while revenues jumped 53% to $213 million.
Management raised its full-year yield expectation to approximately 4.45%, citing targeted enrollment campaigns, member referrals and renewals. Faster member adoption among new clients and stronger engagement among legacy clients are also supporting the trend. These initiatives provide a durable foundation for continued revenue growth.
AI and Automation Are Expanding Operating Leverage: Hinge Health is using AI and automation to scale care delivery while controlling costs. Gross margin expanded more than 400 basis points year over year to 87% in the second quarter. Operating margin also increased 1,000 basis points to 29%.
The company is serving more members without proportional increases in care delivery costs, supported by greater care team efficiency and AI-driven workflows. Management expects 2026 operating income of $236-$244 million, up from its previous guidance of $217-$227 million.
Migraine Care Broadens HNGE’s Growth Opportunity: Hinge Health’s expansion beyond musculoskeletal care is creating another growth avenue. The Migraine Care Program had more than 450 clients covering more than 5 million lives by the second quarter, following its launch earlier in 2026. The offering combines AI-powered tracking, exercise therapy, care-team support and the Enso neuromodulation device.
Management expects only a modest revenue contribution in 2026, with a more meaningful impact beginning in 2027. The rapid client adoption highlights the ability of Hinge Health to leverage its existing platform and distribution network across new conditions.
GI Expansion Adds a New Growth Engine: Hinge Health is also expanding into gastrointestinal care through its planned $105 million acquisition of Cylinder Health. The deal adds nearly 100 clients covering 2 million lives and established relationships with major health plans and PBMs.
Hinge Health expects Cylinder to contribute $7-$8 million of revenues during the remaining months of 2026, with a much larger opportunity from 2027 onward. GI is a natural extension of the company’s multi-product strategy, as it can leverage the same technology, distribution channels and commercial relationships.
Image Source: Zacks Investment Research
HNGE’s Estimates
The Zacks Consensus Estimate for HNGE’s 2026 and 2027 earnings per share (EPS) implies a year-over-year decline of 4.6% and growth of 31.4%, respectively, to $2.50 and $3.29. In the past 60 days, the consensus mark for the company's 2026 EPS has improved by a cent.
Revenues for 2026 are projected to grow 44.6% to $850.3 million and another 25.4% to $1.07 billion in 2027.
Image Source: Zacks Investment Research
Risks and Challenges
HNGE’s rapid expansion also brings execution risks. The company is entering multiple new care categories while continuing to scale its core MSK business. The success of Migraine Care and the planned integration of Cylinder Health will depend on effective product development, client adoption and execution.
Member yield is also becoming increasingly important to the growth outlook. Any moderation in enrolment, engagement or renewals could weigh on billings and revenue. In addition, HNGE operates in a competitive digital healthcare market, where maintaining its strong win rates and client relationships will remain critical.
Conclusion
HNGE’s strong 2026 performance reflects a business that is scaling rapidly while becoming increasingly profitable. Robust revenue and billings growth, improving member yields, AI-driven efficiency and strong free cash flow point to a business model gaining operating leverage. At the same time, Migraine Care and the entry into GI are giving HNGE additional avenues to expand beyond its core MSK market. The company’s raised 2026 outlook and strong commercial pipeline further support the growth story.
However, execution across new products and the ability to sustain member engagement will remain key. With a Zacks Rank #3 (Hold), investors should weigh HNGE’s attractive growth prospects against the execution risks that come with its rapid expansion.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.